交易激励
转换抑制
法尼甾体X受体
核受体
转录因子
孕烷X受体
生物
相扑蛋白
细胞生物学
化学
癌症研究
基因
生物化学
泛素
作者
Danielle A.A. Hollman,Alexandra Milona,Karel J. van Erpecum,Saskia W.C. van Mil
标识
DOI:10.1016/j.bbalip.2012.07.004
摘要
The farnesoid X receptor (FXR) is a ligand-activated transcription factor belonging to the nuclear receptor (NR) superfamily. FXR plays an important role in positively regulating genes (transactivation) involved in bile acid homeostasis, fat and glucose metabolism. Recently, it has become clear that an additional important role for FXR consists of downregulating genes involved in inflammation. Because of this broad spectrum of regulated genes, therapeutically targeting FXR with full agonists will likely result in adverse side effects, in line with what is described for other NRs. It may therefore be necessary to develop selective FXR modulators. However, the molecular mechanisms that distinguish between FXR-mediated transactivation and transrepression are currently unknown. For other NRs, post-translational modifications such as SUMOylation and phosphorylation have been reported to be unique to either transactivation or transrepression. Here, we review current knowledge on post-translational regulation of FXR with respect to transactivation and transrepression. Ultimately, increased understanding of the different mechanisms of transactivation and transrepression of nuclear receptors will aid in the development of NR drugs with fewer side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI